Pharma BD Deal Intelligence
In June 2012, AC Immune entered its second exclusive worldwide license and research collaboration with Genentech (a member of the Roche Group), covering AC Immune's anti-tau antibody program — the asset that became semorinemab. AC Immune received an undisclosed upfront payment (~CHF 59M / $68M) and was eligible for milestones exceeding CHF 400 million (~$418M) across Alzheimer's disease and other indications, plus tiered royalties. The pact extended a relationship begun with the companies' 2006 anti-amyloid-beta collaboration on crenezumab. Roche/Genentech returned global rights to both crenezumab and semorinemab to AC Immune in 2024, ending the ~18-year alliance after the antibodies failed to demonstrate sufficient clinical benefit.